Humacyte, Inc. (HUMA) Financial Analysis & Valuation | Quarter Chart
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platfo... more
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengi... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $98.38M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Laura E. Niklason |
| IPO Date | 2020-12-01 | CAGR | -16.9% |
| Employees | 184 | Website | www.humacyte.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
HUMA chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $175.01M | P/E | -0.98 | Forward P/E | -2.37 | PEG | — |
| P/S | 631.98 | P/B | 59.84 | P/CF | -19.31 | P/FCF | -13.73 |
| Sales | $2.12M | Sales 1Y | -73.64% | Sales 3Y | 6741.94% | Sales 5Y | 12.64% |
| EPS | $-0.6 | EPS 1Y | 13.11% | EPS 3Y | -54.14% | EPS 5Y | -93.13% |
| Sales QoQ | -17.98% | EPS QoQ | 79.78% | Sales QoQ Avg | 25.05% | EPS QoQ Avg | 5.33% |
| Gross Margin | -666.81% | Operating Margin | -5240.78% | Profit Margin | -4560.82% | ROCE | -90.27% |
| ROA | -70% | ROE | -938% | Altman Z Score | -8.64 | Piotroski Score | 3 |
| Current Ratio | 6.21 | Quick Ratio | 5.74 | Cash Ratio | 5.35 | Op. CF Ratio | -1.48 |
| Debt/Equity | 2.12 | Debt/Assets | 0.48 | Lt Debt/Equity | 2.07 | Lt Debt/Cap. | 0.67 |
| Intrst Cov. | -10.8 | Inventory Turnover | 2.33 | Asset Turnover | 0.02 | Receivables Turnover | 6.43 |
| Enterprise Value | $175.01M | P/E Ratio | -0.98 |
| Forward P/E | -2.37 | PEG Ratio | — |
| P/S Ratio | 631.98 | P/B Ratio | 59.84 |
| P/CF Ratio | -19.31 | P/FCF Ratio | -13.73 |
| EPS | $-0.6 | EPS Growth 1Y | 13.11% |
| EPS Growth 3Y | -54.14% | EPS Growth 5Y | -93.13% |
| Revenue Growth 1Y | -73.64% | Gross Margin | -666.81% |
| Operating Margin | -5240.78% | Profit Margin | -4560.82% |
| ROE | -938% | ROA | -70% |
| ROCE | -90.27% | Current Ratio | 6.21 |
| Quick Ratio | 5.74 | Cash Ratio | 5.35 |
| Debt/Equity | 2.12 | Interest Coverage | -10.8 |
| Altman Z Score | -8.64 | Piotroski Score | 3 |
Humacyte, Inc. (HUMA) valuation & financials
Humacyte, Inc. (HUMA) has a market capitalization of $98.38M and trades at a price-to-earnings ratio of -1.0. It operates in the Healthcare sector (Biotechnology).
Humacyte, Inc.'s revenue grew -73.6% over the last year.
Humacyte, Inc.'s next earnings report is scheduled for November 11, 2026 before market open (provider scheduled date); analysts estimate EPS of $-0.09. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)